ライフサイエンスコーパス: conjugated estrogen

1 hosphamide 750 mg/m2 intravenously on day 1, conjugated estrogens 0.625 mg orally twice daily on days

2 r study, we investigated the effects of oral conjugated estrogen (0.625 mg per day) in 30 postmenopau

3 l women, mean age 63.3+/-7.1 years, to daily conjugated estrogens (0.625 mg) with medroxyprogesterone

4 ransdermal estradiol (200 microgram/d), oral conjugated estrogens (0.625 mg/d), or placebo.

5 therapy with alendronate, 10 mg/d (n = 92); conjugated estrogen, 0.625 mg/d (n = 143); alendronate a

6 rticipants were randomly assigned to receive conjugated estrogens, 0.625 mg/d, plus trimonthly medrox

7 to 9 months of oral therapy with placebo or conjugated estrogens, 0.625 mg/d, plus trimonthly medrox

8 nd, randomized administration of intravenous conjugated estrogens (1.25 mg) or placebo in men with ma

9 Conjugated estrogens acutely abolish abnormal CPT-induce

10 diovascular disease, to evaluate use of oral conjugated estrogen alone (0.625 mg/day) and breast canc

11 were either consistent current users of oral conjugated estrogen alone (0.625 mg/day) or never users

12 rease in breast cancer risk with use of oral conjugated estrogen alone (0.625 mg/day), but a small in

13 Conjugated estrogen, alone or combined with progestin th

14 e randomly assigned to receive 0.625 mg/d of conjugated estrogens and 2.5 mg of medroxyprogesterone a

15 mly assigned to receive hormone therapy with conjugated estrogens and medroxyprogesterone acetate or

16 eucovorin, and hormonal synchronization with conjugated estrogens and tamoxifen.

17 , but 50 women taking alendronate, 81 taking conjugated estrogen, and 41 taking combination therapy w

18 In the environment, conjugated estrogens are nontoxic but may hydrolyze to t

19 The conjugated estrogen /: bazedoxifene tissue-selective est

20 Conjugated estrogen, both alone and in combination with

21 rogens are also of potential concern because conjugated estrogens can be easily converted to potent f

22 In contrast, eight weeks of oral conjugated estrogens caused a more than twofold increase

23 rmal estradiol (E(2)) (100 microg/day), oral conjugated estrogen (CEE) (0.625 mg/day), or placebo.

24 The intervention was 1 g of conjugated estrogen cream (0.625 mg/g) or placebo, inser

25 among women taking 0.625 mg or more of oral conjugated estrogen daily (relative risk, 1.35 [CI, 1.08

26 Furthermore, 0.3 mg of oral conjugated estrogen daily is associated with a reduction

27 s of treatment with active drug (0.625 mg of conjugated estrogen daily, plus 5 mg of medroxyprogester

28 ized to receive intravenous followed by oral conjugated estrogen for 21 days, intravenous estrogen fo

29 To identify the fate of a conjugated estrogen in natural agricultural soils, batch

30 exposure to oral contraceptive steroids and conjugated estrogens increases the risk for gallstones.

31 idase, enzymes involved in the metabolism of conjugated estrogens, is called the "estrobolome." There

32 ardiovascular effects of daily doses of oral conjugated estrogen lower than 0.625 mg are unknown, and

33 rogen, 0.625 mg/d (n = 143); alendronate and conjugated estrogen (n = 140); or placebo (n = 50).

34 pectively) but not a high dose (>0.625 mg of conjugated estrogen or its equivalent).

35 G/5G genotype should influence the choice of conjugated estrogens or ACE inhibition for the treatment

36 rmed in the same women receiving intravenous conjugated estrogens or sublingual estradiol.

37 Both conjugated estrogens [PAI-1 antigen from 12.5 (7.6, 17.4

38 fied coronary disease to receive 0.625 mg of conjugated estrogen per day, 0.625 mg of conjugated estr

39 0.625 mg of conjugated estrogen plus 2.5 mg of medroxyprogesterone a

40 of conjugated estrogen per day, 0.625 mg of conjugated estrogen plus 2.5 mg of medroxyprogesterone a

41 Treatment with oral conjugated estrogen plus medroxyprogesterone acetate was

42 days, intravenous estrogen followed by oral conjugated estrogen plus medroxyprogesterone for 21 days

43 omen (n=2763) were randomly assigned to take conjugated estrogen plus progestin or placebo.

44 with coronary disease who were randomized to conjugated estrogen plus progestins or identical placebo

45 e randomly assigned to receive 0.625 mg/d of conjugated estrogens plus 2.5 mg of medroxyprogesterone

46 evels during therapy (r= -0.631, P<0.001 for conjugated estrogen; r = -0.507, P=0.004 for combined th

47 strogen (equivalent to <0.625 or 0.625 mg of conjugated estrogen, respectively) but not a high dose (

48 proved (and FDA-approved in combination with conjugated estrogens) selective estrogen receptor (ER) m

49 Administration-approved in combination with conjugated estrogens) selective estrogen receptor (ER) m

50 ACE inhibition with ramipril and conjugated estrogens similarly decrease PAI-1 antigen co

51 ogestin may enhance the estrogenic effect of conjugated estrogen so the combination may be more biolo

52 Two conjugated estrogens that are not Mrp2 substrates did no

53 Among women taking oral conjugated estrogen, the risk for coronary events was si

54 d with increases in D-dimer levels both when conjugated estrogen was given alone (r= -0.572, P=0.001)

55 mong generally healthy postmenopausal women, conjugated estrogens with progestin did not confer prote

56 ity include the agonists 17beta-estradiol or conjugated estrogens with the antagonists tamoxifen, ral

57 Compared to free estrogens, conjugated estrogens would be more mobile in the environ